CoChat
Sign Up
Cited by 85Anxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesParkinson's Disease Mechanisms and TreatmentsPsychological Treatments and Assessments

A waitlist-controlled trial of group cognitive behavioural therapy for depression and anxiety in Parkinson’s disease

Open access
Troeung, Lakkhina, Egan, Sarah J, Gasson, Natalie·2014·BMC Psychiatry
DOI 10.1186/1471-244x-14-19PMC PMC3907935
Open this paper in CoChat — free accountOpen PDF

Abstract

BACKGROUND: The aim of this study was to evaluate the efficacy of a group Cognitive Behavioural Therapy (CBT) treatment for depression and anxiety in Parkinson's disease (PD). METHODS: A waitlist-controlled trial design was used. Eighteen adults with PD and a comorbid DSM-IV-TR diagnosis of depression and/or anxiety were randomised to either Intervention (8-week group CBT treatment) or Waitlist (8-week clinical monitoring preceding treatment). The Depression, Anxiety, Stress Scale-21 (DASS-21) was the primary outcome. Assessments were completed at Time 1 (pretreatment), Time 2 (posttreatment/post-waitlist) and 1-month and 6-month follow-ups. RESULTS: At Time 2, participants who received CBT reported greater reductions in depression (M(change) = -2.45) than Waitlist participants (M(change) = .29) and this effect was large, d = 1.12, p = .011. Large secondary effects on anxiety were also observed for CBT participants, d = .89, p = .025. All treatment gains were maintained and continued to improve during the follow-up period. At 6-month follow-up, significant and large effects were observed for both depression (d = 2.07) and anxiety (d = 2.26). CONCLUSIONS: Group CBT appears to be an efficacious treatment approach for depression and anxiety in PD however further controlled trials with larger numbers of participants are required. TRIAL REGISTRATION: Australian New Zealand Clinical Trials Registry (Trial ID: ACTRN12610000455066).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1471-244x-14-19

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Current evidence from experimental studies suggests CBT is superior to TAU for improving low mood in PD, when delivered individually, in a group, over the phone, or via the internet.

    “The current evidence from experimental studies suggests that CBT is superior to TAU for improving low mood in PD, either when delivered individually (Dobkin, Menza, Allen, Gara, et al., 2011; Wuthrich & Rapee, 2019) or in a group (Troeung et al., 2014), as well as over the phone (Dobkin et al., 2020) and the internet (Kraepelien et al., 2020).”

    From Psychological interventions for people with Parkinson's disease in the early 2020s: Where do we stand? (2021) · cites this paper as Troeung et al., 2014

    The Discussion reports that group CBT produced significantly greater improvement in depression than the waitlist condition in people with Parkinson’s disease. The Methods describe that comparator as eight weeks of clinical monitoring, with existing medication continued but no new treatment initiated; the paper does not identify it as treatment as usual (TAU). (LLM, conf=0.87)

    Experimental — accuracy not yet measured

  • Another RCT found significant and large improvement effects for anxiety with group CBT compared to waitlist controls at post-intervention and at 1-month and 6-month follow-ups.

    “Another similarly sized RCT (Troeung, Egan, & Gasson, 2014) compared group CBT to waitlist controls, and found significant and large improvement effects for anxiety at postintervention, as well as at 1-month and 6-month follow-ups.”

    From Psychological interventions for people with Parkinson's disease in the early 2020s: Where do we stand? (2021) · cites this paper as Troeung, Egan, & Gasson, 2014

    The Results report significant, large anxiety improvements after treatment and at one- and six-month follow-up. However, the Methods state that follow-up analyses were uncontrolled because waitlist participants received CBT after the initial waiting period; the follow-up effects were not comparisons with waitlist controls. The Limitations section also says that partial non-randomisation prevented the study from being classed as a true RCT. (LLM, conf=0.92)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

No citation lists for this paper

No citation lists for this paper yet — checked again daily.

References 47 · Cited by 85

Research works printed but not linked: 27

  1. Weintraub D Burn DJ Parkinson’s disease: the quintessential neuropsychiatric disorder Mov Disord 2011 26 1022 1031 10.1002/mds.23664 21626547 PMC3513835 · DOI
  2. Dissanayaka NN Sellbach A Matheson S Anxiety disorders in Parkinson’s disease: prevalence and risk factors Mov Disord 2010 25 838 845 10.1002/mds.22833 20461800 · DOI
  3. Behar M Srivastava AK Pandey RM Quality of life in patients with Parkinson’s disease Parkinsonism Relat Disord 2005 11 221 226 15878582
  4. Chung TH Deane KHO Ghazi-Noori S Rickards H Clarke CE Systematic review of antidepressant therapies in Parkinson’s disease Parkinsonism Related D 2003 10 59 65 10.1016/S1353-8020(03)00108-1 14643994 · DOI
  5. Skapinakis P Bakola E Salanti G Lewis G Kyritisis P Mavreas V Efficacy acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson’s disease: a systematic review and meta-analysis of randomized controlled trials BMC Neurol 2010 10 49 60 10.1186/1471-2377-10-49 20565960 PMC2903535 · DOI
  6. Barone P Poewe W Albrecht S Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial Lancet Neurol 2010 9 575 580 20452823
  7. Chen R Repetitive transcranial magnetic stimulation as treatment for depression in Parkinson’s disease Mov Disord 2010 25 2272 2273 10.1002/mds.23266 20740486 · DOI
  8. Black KJ A new(old) treatment option for depression in Parkinson’s disease Am J Psychiatry 2011 168 1015 1016 10.1176/appi.ajp.2011.11071124 21969043 · DOI
  9. Dobkin RD Allen LA Menza M Cognitive-behavioural therapy for depression in Parkinson’s disease: a pilot study Mov Disord 2007 22 946 952 10.1002/mds.21455 17377926 · DOI · Paper page
  10. Farabaugh A Locascio JJ Yap L Cognitive-behavioural therapy for patients with Parkinson’s disease and comorbid major depressive disorder Psychosomatics 2010 51 124 129 20332287
  11. Mohlman J Reef DH Chazin D Ong D Georgescu B Tiu J Dobkin RD A novel approach to treating anxiety and enhancing executive skills in an older adult with Parkinson’s disease Clin Case Stud 2010 8 74 90 20419071 PMC2856965
  12. A’Campo LEI Wekking EM Spliethoff-Kamminga NGA Le Cessie S Roos RAC The benefits of a standardized patient education program for patients with Parkinson’s disease and their caregivers Parkinsonism Relat Disord 2010 16 89 95 10.1016/j.parkreldis.2009.07.009 19674927 · DOI
  13. Macht M Gerlich C Ellgring H Schradi M Rusinol AB Crespo M Patient education in Parkinson’s disease: formative evaluation of a standardized program in seven European countries Patient Educ Couns 2007 65 245 252 10.1016/j.pec.2006.08.005 16965885 · DOI
  14. Simons G Thompson SBN Pasqualini S An innovative education programme for people with Parkinson’s disease and their carers Parkinsonism Relat Disord 2006 12 478 485 10.1016/j.parkreldis.2006.05.003 16781881 · DOI
  15. Husaini BA Cummings S Kilbourne B Roback H Sherkat D Levine R Cain VA Group therapy for depressed elderly woman Int J Group Psychother 2004 54 295 319 10.1521/ijgp.54.3.295.40340 15253507 · DOI
  16. Lewinsohn PM Clarke GN Psychosocial treatments for adolescent depression Clin Psychol Rev 1999 19 329 342 10.1016/S0272-7358(98)00055-5 10097874 · DOI
  17. Fischer DJ Himle JA Hanna GL Group behavioral therapy for adolescents with obsessive-compulsive disorder: preliminary outcomes Res Social Work Prac 1998 8 629 636 10.1177/104973159800800601 · DOI
  18. Moher D Hopewell S Schulz KF CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trial BMJ 2010 340 c869 10.1136/bmj.c869 20332511 PMC2844943 · DOI · Paper page
  19. Lecrubier Y Sheehan D Weiller E Amorim P Bonora I Sheehan K Janavs J Dunbar G The M.I.N.I. International Neuropsychiatric Interview (M.I.N.I.) A short diagnostic structured interview: reliability and validity according to the CIDI Eur Psychiatry 1997 12 224 231 10.1016/S0924-9338(97)83296-8 · DOI · Paper page
  20. Lovibond PF Lovibond SH The structure of negative emotional states: comparison of the depression anxiety stress scales (DASS) with the Beck depression and anxiety inventories Behav Res Ther 1995 33 335 343 10.1016/0005-7967(94)00075-U 7726811 · DOI · Paper page
  21. Peto V Jenkinson C Fitzpatrick R PDQ-39: a review of the development, validation and application of a Parkinson’s disease quality of life questionnaire and its associated measures J Neurol 1998 245 S10 S14 10.1007/PL00007730 9617716 · DOI
  22. Beck AT Brown G Steer RA Eidelson JI Riskin JH Differentiating anxiety and depression: a test of the cognitive content-specificity hypothesis J Abnorm Psychol 1987 96 179 183 3680754
  23. Jacobson NS Truax P Clinical significance: a statistical approach to defining meaningful change in psychotherapy research J Consult Clin Psychol 1991 59 12 19 2002127
  24. Veazey C Cook KF Stanley M Lai EC Kunik ME Telephone-administered cognitive behavioural therapy: a case study of anxiety and depression in Parkinson’s disease J Clin Psychol Med Settings 2009 16 243 253 10.1007/s10880-009-9167-6 19404724 · DOI · Paper page
  25. Rachman S Rapid and not-so-rapid responses to cognitive behavioural therapy Clin Psychol-Sci PR 1999 6 293 294 10.1093/clipsy/6.3.293 · DOI
  26. Leentjens AFG Vreeling FW Luijckx GJ Verhey FRJ SSRIs in the treatment of depression in Parkinson’s disease Int J Geriatr Psychiatry 2003 18 552 554 10.1002/gps.865 12789682 · DOI
  27. Qureshi SU Amspoker AB Calleo JS Kunik ME Marsh L Anxiety disorders, physical illnesses and health care utilization in older male veterans with Parkinson disease and comorbid depression J Geriatr Psychiatry Neurol 2012 25 233 239 10.1177/0891988712466458 23197499 · DOI

Authors
Troeung, L., Egan, S. J., & Gasson, N.
Affiliations
Curtin University (AU)
Corresponding author
Troeung, Lakkhina
ORCID
Venue
BMC Psychiatry
Publisher
Springer Science and Business Media LLC
Published
2014-01-27
Volume
14
Issue
1
Pages
19-19
ISSN
1471-244X (ISSN-L)
DOI
10.1186/1471-244x-14-19
PMC
PMC3907935
OpenAlex
W2017418161
Cited by
85
References
47
Citations by year
2026: 4 · 2025: 3 · 2024: 8 · 2023: 5 · 2022: 7 · 2021: 10 · 2020: 5 · 2019: 10 · 2018: 6 · 2017: 5 · 2016: 7 · 2015: 11 · 2014: 4
FWCI
12.52
Type
journal article
Language
en
Open access
Licence
Locations
  • BMC Psychiatry (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • UWA Profiles and Research Repository (UWA) (submittedVersion, other-oa)
  • eSpace (Curtin University) (submittedVersion, cc-by)
Funders
Curtin University of Technology
Topics
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
  • Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Assessments
Keywords
group cognitive behavioral therapy, Parkinson's disease, depression, anxiety, comorbidities, DASS-21, treatment efficacy, maintenance therapy
MeSH terms
Aged, Anxiety, Australia, Depression, Female, Humans, Male, Middle Aged, New Zealand, Parkinson Disease, Waiting Lists, Comorbidity, Cognitive Behavioral Therapy, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review